Order Article Reprints

Hsu Y-C, Lin P-T, Teng W, Hsieh Y-C, Chen W-T, Su C-W, Wang C-T, Chai P-M, Lin C-C, Lin C-Y, et al. Comparing Lenvatinib/Pembrolizumab with Atezolizumab/Bevacizumab in Unresectable Hepatocellular Carcinoma: A Real-World Experience with Propensity Score Matching Analysis. Cancers. 2024; 16(20):3458. https://doi.org/10.3390/cancers16203458

Hsu, Yu-Chun, Po-Ting Lin, Wei Teng, Yi-Chung Hsieh, Wei-Ting Chen, Chung-Wei Su, Ching-Ting Wang, Pei-Mei Chai, Chen-Chun Lin, Chun-Yen Lin, and et al. 2024. "Comparing Lenvatinib/Pembrolizumab with Atezolizumab/Bevacizumab in Unresectable Hepatocellular Carcinoma: A Real-World Experience with Propensity Score Matching Analysis" Cancers 16, no. 20: 3458. https://doi.org/10.3390/cancers16203458

Hsu, Y.-C., Lin, P.-T., Teng, W., Hsieh, Y.-C., Chen, W.-T., Su, C.-W., Wang, C.-T., Chai, P.-M., Lin, C.-C., Lin, C.-Y., & Lin, S.-M. (2024). Comparing Lenvatinib/Pembrolizumab with Atezolizumab/Bevacizumab in Unresectable Hepatocellular Carcinoma: A Real-World Experience with Propensity Score Matching Analysis. Cancers, 16(20), 3458. https://doi.org/10.3390/cancers16203458